recurrent and refractory mature B-cell lymphoma involving maxillofacial and / or central nervous system involvement
Conditions
Interventions
experimental group:sequential B antigen chimeric antigen receptor T cells
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: Patient's pathology was confirmed as mature BCL with positive target markers, tumor progression or relapse happened during chemotherapy; or tumor recurred after stopping chemotherapy, and there was no efficacy after one course of chemotherapy and partial remission could not be obtained (refer to NCCN guidelins, version 4, 2014) or complete remission can not be achieved after 2 courses of treatment. Aged 1-18 years; patients < 18 years of age have the ability to sign consent; the guardian of the patient or patient delegate signed consent before joining the trial.
Exclusion criteria
Exclusion criteria: Intracranial hypertension or confusion; Symptomatic heart failure or severe arrhythmia; Respiratory failure; With other types of malignancy; Diffuse intravascular coagulation; Serum creatinine and / or urea nitrogen >= 1.5 times normal value; Sepsis or other uncontrollable infections; Uncontrolled diabetes; Serious mental disorder; Skull MRI obvious intracranial lesions; CSF examination leukemia cells> 20/ul; The proportion of blood leukemia cells> 30%; WHO physical status graded >= 3; Organ Transplant Recipients; Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diameter of turmor;blood cell account;immune function;cytokines;complete remission rate;Progression-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| erious adverse events; | — |
Countries
China
Contacts
Public ContactZhang Yonghong
Beijing Boren Hospital
Outcome results
None listed